The agency first approved Orkambi in 2015 for cystic fibrosis patients age 12 and older. Now, the drug can also be used to treat children ages 6 to 11.
Despite the approval, Boston-based Vertex lowered its 2016 sales forecast for the drug from about $1 billion to no more than $990 million.
More articles on supply chain:
US consumer confidence index at highest level in 9 years
Drug reviewers often ditch FDA for pharma industry, research finds
Why patient advocacy groups are silent about high drug prices
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
